Drug Type Small molecule drug |
Synonyms CGP 3466, CGP 3466 maleate, CGP 3466B + [7] |
Target |
Mechanism GAPDH inhibitors(Glyceraldehyde-3-phosphate dehydrogenase liver inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 1 |
First Approval Date- |
RegulationOrphan Drug (US), Orphan Drug (EU) |
Molecular FormulaC19H17NO |
InChIKeyQLMMOGWZCFQAPU-UHFFFAOYSA-N |
CAS Registry181296-84-4 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Amyotrophic Lateral Sclerosis | Phase 2 | BE | 01 Sep 2003 | |
Amyotrophic Lateral Sclerosis | Phase 2 | BE | 01 Sep 2003 | |
Amyotrophic Lateral Sclerosis | Phase 2 | FR | 01 Sep 2003 | |
Amyotrophic Lateral Sclerosis | Phase 2 | FR | 01 Sep 2003 | |
Amyotrophic Lateral Sclerosis | Phase 2 | DE | 01 Sep 2003 | |
Amyotrophic Lateral Sclerosis | Phase 2 | DE | 01 Sep 2003 | |
Amyotrophic Lateral Sclerosis | Phase 2 | IT | 01 Sep 2003 | |
Amyotrophic Lateral Sclerosis | Phase 2 | IT | 01 Sep 2003 | |
Amyotrophic Lateral Sclerosis | Phase 2 | NL | 01 Sep 2003 | |
Amyotrophic Lateral Sclerosis | Phase 2 | NL | 01 Sep 2003 |
Phase 1 | 20 | (Cohort 1 0.02 mg/kg/Day) | ruycyyvgfn(eadrcdbjjv) = efocanlzgm hirwtnfwwi (xtlxbawtnt, pqqvcmtizb - iwfuynwour) View more | - | 20 Sep 2019 | ||
(Cohort 2 0.08 mg/kg/Day) | ruycyyvgfn(eadrcdbjjv) = rkkrugguna hirwtnfwwi (xtlxbawtnt, ccrkbxrupd - vlecptlmtz) View more |